Back to Archived News
PhytoPharmacon Strengthens Intellectual Property Position
Monday, May 19, 2008
Research Triangle Park, NC -- PhytoPharmacon LLC (formerly SaviPu Pharmaceuticals), a privately owned biopharmaceutical company, announced today the issuance of a new patent. The issued patent covers Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases. The company is currently developing a Myriceric Acid A analog for the treatment of Androgen Refractory Prostate Cancer, one of the therapeutic areas of focus for PhytoPharmacon.
The patent also includes pharmaceutical compositions, methods of treatment for a number of other important inflammatory and cardiovascular diseases particularly arthritis, inflammatory bowel disease, asthma and COPD, osteoporosis, Alzheimer's, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer and cachexia.
According to Dr. Cipau, CEO, the company has a number of patent filings, which further strengthens its intellectual property position in botanical drug development and commercialization. PhytoPharmacon has identified drug candidates in oncology, cardiovascular disease, and the anti-inflammatory field including asthma. By selecting drug candidates whose efficacy and safety have already been established over hundreds of years in China, India, USA and Europe, the company expects to be able to reduce the time taken to bring these proprietary botanical drugs to market.
The company founder and President, Dr. Ven Subbiah, recently presented at the Banagalore Bio Conference. At the presentation, Dr. Subbiah covered company strategy and an update on the development of its lead product for the treatment of asthma. Working within the recently issued FDA guidance in this area, the company strategy is to use its broad product and technology platform to develop a portfolio of botanical prescription drugs.
Gabriel Cipau, M.B.A., Ph.D. recently joined PhytoPharmacon as Chief Executive Officer. Dr. Cipau served as president of Nippon Wellcome Japan and Board member of Wellcome Foundation PLC, UK. He was also CEO of several pharmaceutical and biotechnology companies including Catalytica Pharmaceuticals, Copley Pharmaceuticals, Biolex and PhaseBio.
The company is currently seeking a $1.5 million Series A investment to fund the development of its botanical prescription drug portfolio.
PhytoPharmacon is a privately owned biopharmaceutical company dedicated to the discovery, development and commercialization of a portfolio of botanically derived pharmaceuticals that inhibit multiple disease specific pathways.
For more information, visit our website at www.phytopharmacon.com.
Back to Archived News